Strong enthusiasm for novel modalities is tempered by neurologists’ demands for clinically meaningful endpoints and data superiority, according to Spherix
Exton, PA., October 31, 2025 — Spherix Global Insights has announced the launch of its latest Market Dynamix™ service, PD-1
New analysis from Spherix Global Insights reveals 90% retention on first-line gMG biologics, with Alexion’s Ultomiris® and argenx’s Vyvgart® (IV)
Exton, PA., October 28, 2025 – The membranous nephropathy (MN) treatment paradigm is on the brink of transformation, with physicians signaling
Despite two recent FDA approvals, two-thirds of physicians report high unmet need in CSU, highlighting potential for clinical advancement, according
New Spherix Global Insights data reveal growing physician demand for therapies that reduce treatment burden and elevate patient experience. EXTON,
With multiple late-stage assets advancing, manufacturers have a near-term opportunity to drive much-needed disease education and shape therapeutic direction. EXTON,
Inaugural coverage will include multiple myeloma, myelodysplastic syndrome and B-cell malignancies (large B-cell lymphoma and chronic lymphocytic leukemia). EXTON, PA.,
New payer research highlights tightening formularies, shifting contracting models, and rising cost-containment pressures heading into 2026. EXTON, PA, October 14,
Physician sentiment captured in Spherix Global Insights’ research highlights high expectations for dual TYK2/JAK1 inhibition, with continued unmet needs across
New research reveals cautious optimism as physicians weigh transformative potential against safety, access, and the enduring role of biologics and
New data from Spherix Global Insights uncover how hematologists are defining the “right patient” for gene therapy, balancing promise with
